To the full analysis
Buyback calculator for Autolus Therapeutics
Autolus Therapeutics stock: key metrics
AUTLAutolus Therapeutics had an operating margin of −372.4% and a return on invested capital (ROIC) of −35.5% in fiscal 2025.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Daily figure as of 13 Nov 2026
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2014 | 100.0% | −8,613.8% | −7,931.1% |
| 2015 | 60.6% | −1,186.1% | −1,035.5% |
| 2016 | 40.4% | −1,383.2% | −1,165.2% |
| 2017 | −4,520.4% | −5,503.7% | −2,976.5% |
| 2019 | −3,525.1% | −8,513.8% | −4,258.9% |
| 2020 | −7,765.2% | −17,675.4% | −8,285.4% |
| 2021 | 100.0% | −9,314.8% | −9,429.1% |
| 2022 | 100.0% | −2,307.0% | −2,403.0% |
| 2023 | 100.0% | −10,583.1% | −12,272.3% |
| 2024 | −1,293.5% | −2,385.6% | −2,180.5% |
| 2025 | −27.8% | −372.4% | −381.4% |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2014 | −36.0% | −60.9% | −32.9% |
| 2015 | −40.9% | −43.6% | −36.7% |
| 2016 | −13.8% | −21.1% | −13.3% |
| 2017 | −15.2% | −26.1% | −14.3% |
| 2019 | −48.6% | −69.6% | −40.8% |
| 2020 | −67.7% | −87.8% | −48.3% |
| 2021 | −45.4% | −34.6% | −35.0% |
| 2022 | −49.8% | −27.5% | −30.4% |
| 2023 | −100.0% | −36.7% | −55.5% |
| 2024 | −51.6% | −36.2% | −28.2% |
| 2025 | −100.0% | −35.5% | −48.9% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 30 Jun 2019)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.